Zhejiang Tailin Bioengineering Co Ltd (SHE:300813) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Tailin Bioengineering Co Ltd (300813)
Zhejiang Tailin Bioengineering Co Ltd (SHE:300813) has a market capitalization of $385.56 Million (CN¥2.63 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13712 globally and #4111 in its home market, demonstrating a 6.36% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Tailin Bioengineering Co Ltd's stock price CN¥21.74 by its total outstanding shares 121199219 (121.20 Million). Also see Zhejiang Tailin Bioengineering Co Ltd (300813) total assets for a full breakdown of the balance sheet.
Zhejiang Tailin Bioengineering Co Ltd Market Cap History: 2020 to 2026
Zhejiang Tailin Bioengineering Co Ltd's market capitalization history from 2020 to 2026. Data shows growth from $407.47 Million to $385.56 Million (8.96% CAGR). Also see 300813 cash generation efficiency for how efficiently the company converts equity into cash flow.
Zhejiang Tailin Bioengineering Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Tailin Bioengineering Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 300813 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.30x
Zhejiang Tailin Bioengineering Co Ltd's market cap is 1.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
26.43x
Zhejiang Tailin Bioengineering Co Ltd's market cap is 26.43 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $407.47 Million | $200.24 Million | $48.39 Million | 2.03x | 8.42x |
| 2021 | $833.47 Million | $283.25 Million | $63.53 Million | 2.94x | 13.12x |
| 2022 | $623.93 Million | $373.88 Million | $79.69 Million | 1.67x | 7.83x |
| 2023 | $432.74 Million | $269.86 Million | $19.67 Million | 1.60x | 22.00x |
| 2024 | $306.29 Million | $349.00 Million | $13.05 Million | 0.88x | 23.47x |
| 2025 | $435.76 Million | $334.41 Million | $16.49 Million | 1.30x | 26.43x |
Competitor Companies of 300813 by Market Capitalization
Companies near Zhejiang Tailin Bioengineering Co Ltd in the global market cap rankings as of September 19, 2026. Review 300813 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Zhejiang Tailin Bioengineering Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Zhejiang Tailin Bioengineering Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Zhejiang Tailin Bioengineering Co Ltd's market cap moved from $407.47 Million to $ 385.56 Million, with a yearly change of 8.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥385.56 Million | -11.52% |
| 2025 | CN¥435.76 Million | +42.27% |
| 2024 | CN¥306.29 Million | -29.22% |
| 2023 | CN¥432.74 Million | -30.64% |
| 2022 | CN¥623.93 Million | -25.14% |
| 2021 | CN¥833.47 Million | +104.55% |
| 2020 | CN¥407.47 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Zhejiang Tailin Bioengineering Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $385.56 Million USD |
| MoneyControl | $385.56 Million USD |
| MarketWatch | $385.56 Million USD |
| marketcap.company | $385.56 Million USD |
| Reuters | $385.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Tailin Bioengineering Co Ltd
Zhejiang Tailin BioEngineering Co.,Ltd engages in the research and development, production, and sale of microbial detection, contamination control, process analysis, and inhibition protection in the life sciences field in China and internationally. The company primarily offers aseptic production and contamination control equipment, microbial testing products, and organic matter analysis technolog… Read more